Transpara (2.1.0)

Transpara (2.1.0) is a radiological computer-assisted detection and diagnosis software that enhances breast cancer detection in mammography and tomosynthesis by identifying suspicious regions and assessing malignancy likelihood. Its methodology leverages sophisticated algorithms, including a new Temporal Analysis feature, to improve diagnostic accuracy, as demonstrated by non-inferior and superior performance compared to predicate devices in non-clinical testing.

ScreenPoint Medical B.V. has developed Transpara (2.1.0), medical software designed as a radiological computer-assisted detection and diagnosis aid. Its primary purpose is to assist physicians in interpreting full-field digital mammography and digital breast tomosynthesis exams concurrently. The device identifies suspicious regions for breast cancer, assessing their likelihood of malignancy by providing scores for calcification groups, soft-tissue regions, and an overall exam score. However, it is explicitly stated that patient management decisions should not be made solely based on Transpara's analysis, indicating its role as a supportive tool rather than a definitive diagnostic one. Following a comprehensive review, Transpara (2.1.0) received a determination of substantial equivalence to other legally marketed medical devices, allowing its market entry subject to general regulatory controls. Non-clinical performance data, derived from extensive software verification and standalone tests on a large, independent dataset, demonstrated that the device's breast cancer detection performance is non-inferior and, in some aspects, superior to its predicate device, particularly with the introduction of its new Temporal Analysis feature. The evaluation concluded that the technological differences in Transpara do not raise new questions concerning its safety and effectiveness for its intended use.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific algorithms or deep learning methodologies does Transpara utilize to identify suspicious regions and assess malignancy likelihood?; How does the new Temporal Analysis feature improve detection performance, and what are its limitations or specific benefits across different breast densities or cancer types?; What was the size and demographic breakdown of the independent dataset used for non-clinical performance testing, and does it represent diverse patient populations?; Are there ongoing or planned clinical trials to evaluate Transpara's impact on patient outcomes, such as biopsy rates, false positives, or interval cancers, in a real-world setting?; How does Transpara integrate with existing radiology workflows, and what training or infrastructure is required for optimal implementation and use by clinicians?